On 27 June 2018, NICE Appraisal Committee will meet in Manchester to discuss draft recommendation for Spinraza provision in England and Wales. Parts of the meeting will be open to the public and you are welcome join.
Today Roche announced they decision to stop the development of olesoxime, a neuroprotective drug that showed benefit in spinal muscular atrophy. Below is their statement:
Open letter to Biogen following SMC recommendation
Another potential treatment for SMA is progressing fast
Biogen's statement re. Scottish decision on nusinersen availability
Scotland annouces very restricted access to Spinraza, depriving the majority of SMA patients of an effective treatment
Australia will allocate 240 million Australian dollars to fund the break-through Spinraza treatment for those with spinal muscular atrophy.